Full Press Release Details
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Further to our press release dated November
6, 2015 with regard to the receipt of Warning Letter from US FDA for three of our sites (API manufacturing facilities at Srikakulum,
Andhra Pradesh and Miryalguda, Telengana, and Oncology formulation manufacturing facility at Duvadda, Visakhapatnam, Andhra Pradesh);
we have now been informed by US FDA that based on its evaluation, we have addressed the violations and deviations contained in
the said Warning Letter.
With this the said Warning Letter has been
This is for your information.
| /s/ Sandeep Poddar | ||
| Sandeep Poddar |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)